Browsing by Author "Kalogera-Fountzila, Anna"
Now showing items 1-17 of 17
-
Article
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
Pentheroudakis, George; Kostadima, Lida; Fountzilas, George; Kalogera-Fountzila, Anna; Klouvas, G. D.; Kalofonos, H. P.; Pavlidis, Nicholas (2004)Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...
-
Article
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study
Fountzilas, George; Nikolaides, C.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Samelis, G.; Aravantinos, Gerasimos; Pavlidis, Nicholas (2000)A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
Razi, E. D.; Dimopoulos, M. A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Briassoulis, E. Ch; Samantas, E.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Fountzilas, George (2001)The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...
-
Article
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Dimopoulos, M. A.; Papadimitriou, C.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Athanasiades, A.; Nikolaides, C.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1998)Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first- line chemotherapy in patients with advanced breast cancer (ABC). Background: Paclitaxel ...
-
Article
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...
-
Article
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer
Fountzilas, George; Skarlos, Dimosthenis V.; Giannakakis, T.; Athanasiades, A.; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Bamia, C.; Pavlidis, Nicholas; Kosmidis, Paraskevas A. (1994)50 women with advanced breast cancer were treated with an intensified regimen which consisted of high-dose epirubicin (110 mg/m2) every 2 weeks and filgrastim (5 μg/kg) subcutaneously for 13 days, starting 24 h after ...
-
Article
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: A phase I/II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Pectasides, Dimitrios; Kalogera-Fountzila, Anna; Skarlos, Dimosthenis V.; Kalofonos, H. P.; Papadimitriou, C.; Bafaloukos, Dimitrios; Lambropoulos, S.; Papadopoulos, S.; Kourea, H.; Markopoulos, C.; Linardou, H.; Mavroudis, D.; Briassoulis, E. Ch; Pavlidis, Nicholas; Razi, E. D.; Kosmidis, Paraskevas A.; Gogas, H. (2005)Paclitaxel (TaxolR) and carboplatin are an effective combination regimen for treating advanced breast cancer. Gefitinib (IRESSA) is the first epidermal growth factor receptor tyrosine kinase inhibitor to be approved for ...
-
Article
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Stathopoulos, G. P.; Nikolaides, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Nikolaou, A.; Bacoyiannis, Charalambos; Samantas, E.; Papadimitriou, C.; Kosmidis, Paraskevas A.; Daniilidis, J.; Pavlidis, Nicholas (1999)Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, Anna; Maniadakis, N.; Aravantinos, Gerasimos; Syrigos, K.; Bamias, A. T.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H. P.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Pavlidis, Nicholas; Daniilidis, J. (2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...
-
Article
Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group
Fountzilas, George; Athanasiades, A.; Kalogera-Fountzila, Anna; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Briassoulis, E. Ch; Dombros, N.; Loannidis, I.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1997)37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg · min/ml every 4 weeks with G-CSF support. There ...
-
Article
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck: A phase II study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Skarlos, Dimosthenis V.; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Nicolaou, A.; Dombros, N.; Briassoulis, E. Ch; Dinopoulou, M.; Stathopoulos, G. P.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Daniilidis, J. (1997)Background: Paclitaxel has been demonstrated to have significant activity in recurrent or metastatic head and neck cancer (HNC). In addition, the combination of paclitaxel and cisplatin is active in untreated patients with ...
-
Article
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
Fountzilas, George; Athanasiades, A.; Kalogera-Fountzila, Anna; Samantas, E.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Skarlos, Dimosthenis V. (1997)We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent ...
-
Article
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: A hellenic cooperative oncology group phase II study
Fountzilas, George; Ch, F. Tolis; Kalogera-Fountzila, Anna; Misailidou, D.; Tsekeris, P.; Karina, M.; Nikolaou, A.; Samantas, E.; Makatsoris, T.; Athanassiou, E.; Skarlos, Dimosthenis V.; Bamias, A. T.; Zamboglou, N.; Economopoulos, T.; Karanastassi, S.; Pavlidis, Nicholas; Daniilidis, J. (2005)The primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until ...
-
Article
Prognostic factors influencing complete response to treatment and survival of patients with nasopharyngeal cancer
Kalogera-Fountzila, Anna; Kosmidis, Paraskevas A.; Bacoyiannis, Charalambos; Nicolaou, A.; Samantas, E.; Briassoulis, E. Ch; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Daniilidis, J.; Fountzilas, George (1998)The identification of prognostic factors influencing local control and survival of patients with nasopharyngeal cancer (NPC) might help in pointing out those patients who would probably benefit from primary treatment. A ...
-
Article
Radiation and concurrent carboplatin administration in locally advanced head and neck cancer
Fountzilas, George; Skarlos, Dimosthenis V.; Nikolaou, A.; Kalogera-Fountzila, Anna; Tzitzikas, J.; Kosmidis, Paraskevas A.; Makrantonakis, P.; Samantas, E.; Karpasitis, N.; Bacoyiannis, Charalambos; Synodinou, M.; Pavlidis, Nicholas; Vritsios, A.; Daniilidis, J. (1995)Aims and Background: To improve local control in patients with locally advanced inoperable head and neck cancer we administered carboplatin concurrently with radiation. Methods: Thirty-nine patients entered the study. There ...
-
Article
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group Study
Fountzilas, George; Athanasiades, A.; Giannakakis, T.; Briassoulis, E. Ch; Bafaloukos, Dimitrios; Kalogera-Fountzila, Anna; Onienaoum, A.; Kalofonos, H. P.; Pectasides, Dimitrios; Andreopoulou, E.; Bamia, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)Purpose: To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy. Patients and methods: From January 1991 until April ...